Previous Close | 151.97 |
Open | 152.83 |
Bid | 154.32 x 100 |
Ask | 154.48 x 100 |
Day's Range | 150.40 - 155.28 |
52 Week Range | 143.52 - 218.88 |
Volume | |
Avg. Volume | 863,354 |
Market Cap | 19.445B |
Beta (5Y Monthly) | 0.39 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -3.52 |
Earnings Date | May 02, 2024 - May 06, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 222.59 |
CAMBRIDGE, Mass., March 20, 2024--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will host a webcast event to discuss results from the KARDIA-2 Phase 2 study of zilebesiran, an investigational RNAi therapeutic targeting liver-expressed angiotensinogen (AGT) in development for the treatment of hypertension, at the American College of Cardiology (ACC) Scientific Session on Sunday, April 7, 2024 at 7:00 pm ET. The event will include pres
In this article, we will be taking a look at the 30 biggest biotechnology companies in the world. If you do not want to learn about the global biotech market, head straight to the 5 Biggest Biotechnology Companies in the World. In the ever-evolving landscape of biotechnology, several companies like Novo Nordisk, Regeneron, and United […]
CAMBRIDGE, Mass., March 13, 2024--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the launch of the Family Health History Road Trip, its program designed to encourage conversations between family members about their health history so they can discuss with their doctor to better understand their risk for developing an inherited disease like hereditary ATTR (hATTR) amyloidosis. Inspired by the traditional family road trip, the program follows ge